Maharashtra Herald

Hemophilia B Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Hemophilia B Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

July 29
14:24 2020
Hemophilia B Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Hemophilia B – Market Insights, Epidemiology, and Market Forecast-2030”

DelveInsight has launched a new report on “Hemophilia B – Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’sHemophilia B – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of key facts

  • According to the World Federation of Hemophilia (WFH), the total number of cases around the World for Hemophilia B in 2018 was 34,289.
  • Centers for Disease Control and Prevention states Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as hemophilia B, and about half of those affected have a severe form.
  • Hemophilia affects people from all racial and ethnic groups. Additionally about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.
  • As per Santoro, Cristina, et al., 2018, the development of an inhibitor in Hemophilia B is a rare event i.e., 1.5–3% of all patients but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.

 

Report Highlights:

  • The report covers the descriptive overview of Hemophilia B, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hemophilia B epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hemophilia B are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hemophilia B market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hemophilia B market

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/hemophilia-b-market

 

Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein.With the lack of this, the blood cannot clot properly to control bleeding like hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

It is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome. A male who has a hemophilia gene on his X chromosome will have hemophilia. When a female has a haemophilia gene on only one of her X chromosomes, she is a “hemophilia carrier” and can pass the gene to her children.

Sometimes carriers have low levels of clotting factor and have symptoms of hemophilia, including bleeding. Clotting factors are proteins in the blood that work together with platelets to stop or control bleeding.

The main signs and symptoms of hemophilia are excessive bleeding and easy bruising. The child may suffer from recurrent nose bleeds, blood loss from small cuts, long-term bleeding in the mouth from bites, or after removal of a tooth, on-and-off bleeding from a cut or injury, bleeding within the skin or muscle and soft tissue that causes build-up of blood in the area.

The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity. Identification of a hemizygous F9 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/hemophilia-b-market

 

Key companies covered:

  • Novo Nordisk
  • CSL Behring
  • Bioverativ Therapeutics
  • UniQure
  • Pfizer
  • Freeline Therapeutics
  • And Many Others

 

Drugs covered:

  • Rebinyn
  • Idelvion
  • Alprolix
  • Etranacogene dezaparvovec (AMT-061)
  • Fidanacogene elaparvovec
  • FLT180a
  • And Many Others

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/hemophilia-b-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Hemophilia B

3. Competitive Intelligence Analysis for Hemophilia B

4. Hemophilia B: Market Overview at a Glance

5. Hemophilia B: Disease Background and Overview

6. Patient Journey

7. Hemophilia B Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hemophilia B Treatment

11. Marketed Products

12. Emerging Therapies

13. Hemophilia B: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hemophilia B

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/hemophilia-b-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-b-market